Company Filing History:
1 out of 9 
1 out of 117 
Years Active: 2020
Title: Fiona Lanigan: Innovator in Cancer Recurrence Prediction
Introduction
Fiona Lanigan is a notable inventor based in Dublin, Ireland. She has made significant contributions to the field of cancer research, particularly in the prediction of cancer recurrence. Her innovative methods aim to improve patient outcomes through early detection and intervention.
Latest Patents
Fiona Lanigan holds a patent for a method of predicting the risk of recurrence of cancer. This method involves assaying a cancer sample from an individual for positive expression of at least two genes or proteins. The genes selected for this assay include FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367, and TCF19. Positive expression of these genes correlates with an increased risk of cancer recurrence compared to individuals who do not exhibit such expression. This patent represents a significant advancement in personalized cancer treatment.
Career Highlights
Throughout her career, Fiona has worked with prestigious institutions, including Trinity College Dublin and University College Dublin. Her work has been instrumental in advancing cancer research and developing innovative solutions for predicting cancer recurrence.
Collaborations
Fiona has collaborated with esteemed colleagues such as Adrian Bracken and William Gallagher. These partnerships have further enriched her research and contributed to the development of her patented methods.
Conclusion
Fiona Lanigan's contributions to cancer research through her innovative patent highlight her dedication to improving patient care. Her work exemplifies the importance of research and innovation in the fight against cancer.